Intelligent Bio Solutions to Participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 2-3, 2025 

Noble Conference

Share This Post

NEW YORK, November 20, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida. 

Conference Details 
Date:  December 2–3, 2025 
Location:  Florida Atlantic University, Boca Raton, FL  
Presentation Date and Time: Wednesday, December 3, 2025, 11:00 a.m. Eastern Time 
Presentation Location:  Presentation Room 2 

A webcast recording of INBS’s presentation will be available the following day on INBS’s investor relations website, as well as Noble’s website and on Channelchek, for 90 days after the event. 

Interested investors can register to attend here using the discount code INBSNOBLECON. 

For more information about the conference, or to schedule a one-on-one meeting with the INBS management team, please contact your Noble Capital Markets representative or email KCSA Strategic Communications at INBS@ksca.com

About Intelligent Bio Solutions Inc.   

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.    

For more information, visit https://ibs.inc/  

Company Contact   

Intelligent Bio Solutions Inc.    
info@ibs.inc     
LinkedIn | Twitter    

Investor & Media Contact   

Valter Pinto, Managing Director    
KCSA Strategic Communications    
PH: (212) 896-1254    
INBS@kcsa.com   

Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market

Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market

NEW YORK, July 21, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of precision testing, a key component of the Company’s FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection…

INBS Initiates Clinical Study Supporting FDA Clearance

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

NEW YORK, June 16, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for detection of the…

Sign Up

Subscribe to receive the latest news and updates from Intelligent Bio Solutions.